Details
Stereochemistry | MIXED |
Molecular Formula | C22H32N2O6.2ClH |
Molecular Weight | 493.421 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2
InChI
InChIKey=LECFJMMCVCBLPN-UHFFFAOYSA-N
InChI=1S/C22H32N2O6.2ClH/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16;;/h5-8,11-12,21-30H,1-4,9-10,13-14H2;2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.4993 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/195789Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Palliative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Primary | Unknown Approved UseUnknown |
||
Preventing | GYNIPRAL Approved UseGynipral prevents threatened abortion with premature labour. |
PubMed
Title | Date | PubMed |
---|---|---|
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison]. | 1983 Mar |
|
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents. | 1985 Oct |
|
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. | 2001 |
|
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model]. | 2004 Mar |
|
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats. | 2004 Sep |
|
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. | 2009 Jun 19 |
|
Management of foetal asphyxia by intrauterine foetal resuscitation. | 2010 Sep |
Sample Use Guides
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:50:46 GMT 2023
by
admin
on
Sat Dec 16 07:50:46 GMT 2023
|
Record UNII |
97TDI0239I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000128147
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
4323-43-7
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
20321
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
DTXSID60962973
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
224-354-2
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
97TDI0239I
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
SUB34902
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | |||
|
m6013
Created by
admin on Sat Dec 16 07:50:46 GMT 2023 , Edited by admin on Sat Dec 16 07:50:46 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |